Moderna Inc (MRNA) Actualités

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma

Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma PR...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024

Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at...

Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)

The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program, as the third Phase 3 trial for the...

Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence

Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and...

Form 4 - Statement of changes in beneficial ownership of securities

Shareholders of Moderna, Inc. Should Contact The Gross Law Firm Before October 8, 2024 to Discuss Your Rights - MRNA

Shareholders of Moderna, Inc. Should Contact The Gross Law Firm Before October 8, 2024 to Discuss Your Rights...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities